Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 35639881 | A Case of Septic Arthritis of the Elbow Joint in Rheumatoid Arthritis Diagnosed by Arthros | 2022 May 27 | We report a case of methicillin-resistant Staphylococcus aureus (MRSA) septic arthritis of the elbow detected by arthroscopic synovectomy in an 81-year-old woman with rheumatoid arthritis (RA) who was initially diagnosed with an RA flare-up. The patient was administered abatacept, an antirheumatic biological agents, as the synovial fluid culture was negative. Destruction of the joint progressed despite medication, and the patient underwent arthroscopic synovectomy. MRSA was detected in the culture of the synovium that was collected intraoperatively, and septic arthritis was diagnosed. The infection subsided with anti-MRSA antibiotics, but the patient continued to experience moderate pain and limited motion. In RA patients, it might be difficult to differentiate minor findings from infection. Arthroscopic synovectomy is one of a selectable procedure that should be actively considered when infection is suspected. | |
| 35570135 | Vaccination against influenza and pneumococus in patients with rheumatoid arthritis. | 2022 May 12 | BACKGROUND: Vaccination against pathogens such as influenza or pneumococcus is widely recommended for patients with rheumatoid arthritis; the prevalence of adherence to these vaccination programmes in Mexico is not known. METHODS: A cross-sectional descriptive study was carried out, through the application of a survey to adult patients with a diagnosis of rheumatoid arthritis treated in a tertiary hospital in Mexico City. RESULTS: 227 patients were included, vaccination against influenza was found in 31.3% and against pneumococcus in 17.6% of patients, the main reasons for non-compliance with the vaccination schedule were related to ignorance and the recommendation by doctors not to do so. CONCLUSIONS: Compliance with the recommended vaccination schedules in the studied population is lower than those reported in other populations. The most important interventions to improve coverage should be aimed at educating both patients and medical personnel. | |
| 35033462 | Cellular and molecular diversity in Rheumatoid Arthritis. | 2022 Jan 12 | Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease. RA mainly affects synovial joints, with inflammation of the synovial membrane (synovitis), characterised by neo-angiogenesis, hyperplasia of lining layer, and immune cell infiltration that drive local inflammation and, if untreated, can lead to joint destruction and disability. In parallel to the well-known clinical heterogeneity, the underlying synovitis can also be significantly heterogeneous, both at cellular and molecular level, which can at least in part explain why despite the availability of highly effective treatment options, a large proportion of patients are resistant to some individual treatments. The assimilation of recent high-throughput data from analysis at the single-cell level with rigorous and high-quality clinical outcomes obtained from large randomised clinical trials support the definition of disease and treatment response endotypes. Looking ahead, the integration of histological and molecular signatures from the diseased tissue into clinical algorithms may help decision making in the management of patients with Rheumatoid Arthritis in clinical practice. | |
| 32491731 | Leflunomide. | 2022 Jan | Leflunomide is a medication used in the management and treatment of rheumatoid arthritis. It is in the non-biological DMARDs class of medications. This activity reviews the indications, action, and contraindications for leflunomide as a valuable agent in treating and managing rheumatoid arthritis. This activity will highlight the mechanism of action, adverse event profile, and other key factors of leflunomide use in a clinical setting, pertinent to members of the interprofessional team in the care of patients with rheumatoid arthritis and related conditions. | |
| 29763061 | Caplan Syndrome. | 2022 Jan | Caplan syndrome was first described in 1953 by Dr. Anthony Caplan, a provider on the Cardiff pneumoconiosis panel, as radiologic evidence of intrapulmonary nodules in coal miners with a diagnosis of rheumatoid arthritis (RA). It is also called rheumatoid pneumoconiosis. It is a combination of rheumatoid arthritis and pneumoconiosis that manifests as intrapulmonary nodules, which appear well-defined and homogenous on chest x-ray. It is defined as lung nodules in dust-exposed personnel, either with a history of rheumatoid arthritis or develops RA after 5-10 years. There are multiple nodules varying in size from 0.5 to 5 centimeters. The nodules may grow, remain unchanged, disappear, and then reappear. These nodules can cavitate, calcify or develop air-fluid levels. | |
| 34926155 | Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relev | 2022 Jan | Rheumatoid Arthritis (RA) is the most common auto-immune, chronic inflammatory joint disease. Predominantly a musculoskeletal condition with a wide spectrum of skeletal and extra-skeletal manifestations, RA has a significant footfall in orthopaedic clinical practice worldwide. RA is essentially a clinical diagnosis; however, laboratory and radiographic investigations can provide complementary diagnostic and prognostic information about the disease. Early diagnosis and initiation of appropriate management are crucial since RA patients can develop chronic, erosive arthritis if left untreated or if treatment is delayed. Rheumatoid Factor (RF) antibody test is routinely employed for diagnostic purposes in patients with suspected RA. However, RF is present only in 70%-80% of patients with RA and can be non-specific. Therefore, Anti-cyclic citrullinated peptide antibody (ACPA), a novel immunological marker for RA is increasingly being utilised to provide higher specificity and a better prognostic indicator in RA patients. We describe the immunological basis of ACPA test and highlight its current applications in the diagnosis, prognosis and monitoring of RA in clinical practice. | |
| 35608944 | Horse-Specific Cryptosporidium Genotype in Human with Crohn's Disease and Arthritis. | 2022 Jun | We identified an unusual subtype of a Cryptosporidium sp. horse genotype as the cause of cryptosporidiosis in a 13-year-old girl in Poland who was undergoing immunosuppressive treatment for juvenile rheumatoid arthritis and Crohn's disease. The same subtype was identified in a horse the girl had ridden. | |
| 35611110 | Developing A Minimum Data Set for A Rheumatoid Arthritis Registry in Iran. | 2022 Mar | BACKGROUND: Using Minimum Data Set (MDS) is the first step in creating and developing a health care information system; it includes standard and key data elements to capture and manage patient care. AIMS: This study aimed to develop an MDS in order for using it for designing registry of patients with rheumatoid arthritis in Iran. METHODS: This study was conducted at two stages in 2018. In stage one, qualitative method and semi-structured interview were used to identify the registry data elements of patients with rheumatoid arthritis. Collected data was analysed using content analysis method. In stage two, using Delphi method, the developed data set was revised and validated by 15 rheumatologists. Descriptive statistics using SPSS software was used to analyse the data in Delphi. RESULTS: The final MDS included 22 data elements, which were divided into two major categories of management data (including demographic data, and admission and discharge) and clinical data (including patient examination, treatment plans, and medication prescribed by physician). CONCLUSION: Minimum data set is one of the standard data collection tools playing an important role in health care data management. This study presented a MDS as a platform for creating a rheumatoid arthritis registry system in Iran recommended by rheumatologists. | |
| 35595244 | The SUMO components in rheumatoid arthritis. | 2022 May 20 | Small ubiquitin-like modifier (SUMO) proteins can reversibly attach covalently or non-covalently to lysine residues of various substrates. The processes are named SUMOylation and de-SUMOylation, which maintain a dynamic balance in the physiological state, and are regulated by SUMO components. However, the dysregulation of components disturbs the balance and alters the functions of target proteins, which causes the occurrence of diseases. To date, certain SUMO components, including SUMO-1, SUMO-2/3, SAE1/Uba2, Ubc9, PIASs, and SENPs have been found to participate in the pathogenesis of rheumatoid arthritis (RA) and their potential value as therapeutic targets also have been highlighted. In addition, single nucleotide polymorphisms (SNPs) in the SUMO components have been reported to be associated with disease susceptibility. Until now, only the SNP site of SUMO-4 has been reported in RA. Here we provided a systematic overview of the general characteristics of SUMO components and highlighted a summary of their impact on RA. | |
| 35449701 | Does tenosynovitis of the hand detected by B-mode ultrasound predict loss of clinical remi | 2022 Mar | OBJECTIVE: The role of US-detected tenosynovitis (USTS) in the management of rheumatoid arthritis remains controversial. The aim of this study was to investigate whether tenosynovitis can predict a flare in rheumatoid arthritis patients in remission in a real-life cohort. METHODS: Rheumatoid arthritis patients from the Swiss Clinical Quality Management cohort were included in this study if they were in clinical remission, defined by 28-joint disease activity score (DAS28-ESR) <2.6, and had an available B-mode tenosynovitis score. The patients were stratified according to the presence or absence of tenosynovitis (USTS+ vs. USTS-). Cox proportional hazard models were used for time-to-event analysis until the loss of remission, after adjustment for multiple confounders. The impact of baseline US performed early in remission and the advent of flares at different fixed time periods after baseline were investigated in sensitivity analysis. RESULTS: Tenosynovitis was detected in 10% of 402 rheumatoid arthritis patients in remission. At baseline, USTS+ patients in remission had significantly higher DAS28-ESR (mean (SD): USTS- 1.8 (0.5) versus USTS+ 2.0 (0.5); p = 0.0019) and higher additional disease activity parameters, such as physician global assessment, and simplified- and clinical-disease activity index. Joint synovitis detected by B-mode US was associated with tenosynovitis (mean (SD) 7.2 (6.3) in USTS- versus 9.0 (5.4) in USTS+, respectively; p = 0.02). A disease flare was observed in 69% of remission phases, with no differences in the time to loss of remission between USTS+ and USTS- groups. CONCLUSION: While US-detected tenosynovitis was associated with higher disease activity parameters in rheumatoid arthritis patients in clinical remission, it was not able to predict a flare. | |
| 30986010 | Calcium Pyrophosphate Deposition Disease. | 2022 Jan | Calcium pyrophosphate deposition disease (CPPD) is a crystal deposition arthropathy involving the synovial and periarticular tissues. Its clinical presentation may range from being asymptomatic to acute or chronic inflammatory arthritis. Different terms are used to describe the varied phenotypes of calcium pyrophosphate deposition disease. Acute calcium pyrophosphate (CPP) deposition arthritis, frequently referred to as “pseudogout,†presents as an acute flare of synovitis that resembles acute urate arthropathy (gout). Chronic CPP deposition arthritis informally referred to as pseudo-rheumatoid arthritis may present with a waxing and waning clinical course that may last for several months and resemble rheumatoid arthritis involving the wrists and metacarpophalangeal (MCP) joints. The term chondrocalcinosis describes the characteristic radiological finding of intraarticular fibrocartilage calcification. The crystals involved in calcium pyrophosphate deposition disease are composed of calcium pyrophosphate dihydrate and commonly affect larger and weight-bearing joints, including the hips, knees, or shoulders. A large number of patients present with underlying joint disease or metabolic abnormalities predisposing to CPP deposition, including osteoarthritis, trauma, surgery, or rheumatoid arthritis. | |
| 35652065 | Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With | 2022 | It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. They appear to be less frequent when rituximab is used to treat rheumatoid arthritis and systemic lupus perhaps because concomitant steroids are invariably given to these patients with the rituximab which is not necessarily the case with the treatment of B-cell malignancies. | |
| 35488320 | Small interfering RNAs in the management of human rheumatoid arthritis. | 2022 Apr 29 | BACKGROUND: Rheumatoid arthritis (RA) has unclear pathogenesis, but the molecules that feed its inflammatory state are known. Small interfering RNAs (siRNAs) are useful to identify molecular targets and evaluate the efficacy of specific drugs, and can themselves be used for therapeutic purposes. SOURCES OF DATA: A systematic search of different databases to March 2022 was performed to define the role of siRNAs in RA therapy. Twenty suitable studies were identified. AREAS OF AGREEMENT: Small interfering RNAs can be useful in the study of inflammatory processes in RA, and identify possible therapeutic targets and drug therapies. AREAS OF CONTROVERSY: Many genes and cytokines participate in the inflammatory process of RA and can be regulated with siRNA. However, it is difficult to determine whether the responses to siRNAs and other drugs studied in human cells in vitro are similar to the responses in vivo. GROWING POINTS: Inflammatory processes can be affected by the gene dysregulation of siRNAs on inflammatory cytokines. AREAS TIMELY FOR DEVELOPING RESEARCH: To date, it is not possible to determine whether the pharmacological response of siRNAs on cells in vitro would be similar to what takes place in vivo for the diseases studied so far. | |
| 35306593 | Ultrasonographic evaluation of distal femoral and talar cartilage thicknesses in patients | 2022 Mar 19 | INTRODUCTION: The aims of this study were to compare the distal femoral and talar cartilage thicknesses by ultrasonography (US) between patients with early rheumatoid arthritis (RA) and healthy controls and to investigate the potential relationship of these parameters with disease activity and clinical parameters. METHODS: Fifty-five patients with RA with a disease duration of up to 12 months (RA group), and 55 healthy volunteers (control group) were included in the study. The bilateral distal femur and talus cartilage thicknesses of all participants were measured by US and compared between the groups. The relationship of the results with the clinical data of the patients with early RA was investigated. RESULTS: The distal femur (medial, central, and lateral) and talus cartilage thicknesses of both extremities were significantly lower in the RA group. The tender joint count was found to be slightly to moderately negatively correlated with cartilage thickness. However, no correlation was found between the swollen joint count and cartilage thickness. In addition, the disease activity scores were moderately and inversely correlated with cartilage thickness in certain areas. CONCLUSION: The results of this preliminary study using US indicate that the distal femoral and talus cartilage of patients with RA can be affected in the early period, and the cartilage thickness of patients seems to be associated with disease activity. These results may inspire new studies for the evaluation of femoral and talar cartilage with US. Key Points • The distal femoral and talus cartilage thicknesses seem to be affected in the early period of rheumatoid arthritis. • There may be a relationship between the distal femur and talus cartilage thicknesses and disease activity in patients with early rheumatoid arthritis. • The tender joint count appears to be more associated with cartilage thickness than the swollen joint count in patients with early rheumatoid arthritis. | |
| 35280946 | Magnetic resonance imaging of rheumatological diseases. | 2022 | Magnetic resonance imaging (MRI) is extremely useful in the early diagnosis of rheumatologic diseases, as well as in the monitoring of treatment response and disease progression to optimize long-term clinical outcomes. MRI is highly sensitive and specific in detecting the common findings in rheumatologic diseases, such as bone marrow oedema, cartilage disruption, articular erosions, joint effusions, bursal effusions, tendon sheath effusions, and synovitis. This imaging modality can demonstrate structural changes of cartilage and bone destruction years earlier than radiographs. Rheumatoid arthritis, crystal deposition diseases (including gouty arthropathy and calcium pyrophosphate deposition disease), seronegative spondyloarthropathies (including psoriatic arthritis, reactive arthritis, ankylosing spondylitis), and osteoarthritis have characteristic appearances on MRI. Contrast-enhanced MRI and diffusion-weighted imaging can provide additional evaluation of active synovitis. This article describes the MRI findings of normal joints, as well as the pathophysiological mechanisms and typical MRI findings of rheumatoid arthritis, gouty arthritis, calcium pyrophosphate deposition disease, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, and osteoarthritis. | |
| 35537857 | A Case of Central Nervous System Vasculitis Secondary to Rheumatoid Arthritis Treated Succ | 2022 May 11 | Here we report a case of central nervous system vasculitis (CNSV) in rheumatoid arthritis (RA) treated successfully with corticosteroid and mycophenolate. A 53-year-old female with poorly controlled RA presented with unilateral lower motor neurone type 7th cranial nerve palsy. MRI of brain revealed bilateral signal intensity changes in posterior fossa, basal ganglia, periventricular white matter with contrast enhancement. Rheumatoid factor, anti-CCP and C-reactive protein were high. Cerebrospinal fluid analysis showed pleocytosis with elevated protein. Digital subtraction angiography of brain revealed beading pattern in distal branches of anterior, middle and posterior cerebral arteries bilaterally suggestive of central nervous system vasculitis. We treated the patient with Intravenous methyl prednisolone followed by oral prednisolone tapered off in 6 months. Mycophenolate mofetil was started at the dose of 2g per day, along with prednisolone. Sulfasalazine and hydroxychloroquine were also started to treat her arthritis. Patient showed complete neurological improvement, along with significant resolution of the lesions in MRI. | |
| 35313755 | The protective role of glucocerebrosidase/ceramide in rheumatoid arthritis. | 2022 Mar 21 | OBJECTIVE: To clarify the role of glucocerebrosidase (GBA) and Ceramide (Cer) in rheumatoid arthritis (RA). METHODS: GBA-expressing lentivirus were constructed and injected into collagen-induced arthritis (CIA) mice, and compared with CIA mice injected with empty vector. The severity of arthritis and inflammatory mediators were evaluated. Fibroblast-like synoviocytes (FLS) from RA patients were transfected with GBA-expressing lentivirus, or pretreated with C6-Cer. The migration and invasion of FLS, the production of inflammatory cytokines, and the relevant signaling pathways were assessed. RESULTS: In CIA mice, GBA markedly improved arthritis compared to that in the CIA mice, with increased content of proteoglycan and integral cartilage surfaces and tidemarks. The circulating inflammatory mediators, including interleukin (IL)-1β, IL-6, IL-18, and matrix metalloproteinase (MMP)-1, were significantly reduced in CIA mice with GBA overexpression compared to those in CIA mice. GBA and C6-Cer treatment inhibited migration and invasion of FLS, and suppressed production of inflammatory cytokines and activation of the MAPK pathways. CONCLUSION: GBA/Cer exhibited a protective role in CIA mice and RA FLS. These results highlight the potential of targeting GBA/Cer as a therapeutic strategy in RA and warrant further investigation. | |
| 35168509 | A Seven-Joint Ultrasound Score for Differentiating Between Rheumatoid and Psoriatic Arthri | 2022 Feb 15 | BACKGROUND: Differentiating between a seronegative rheumatoid arthritis (RA) and psoriatic arthritis (PsA) presenting only with involvement of the small joints of the hands can be challenging. Implementing musculoskeletal ultrasound (US) to reveal specific patterns of joint and tendon involvement may have an added value in the management of early arthritis. OBJECTIVE: The aim was to investigate whether a seven-joint US score was able to distinguish between patients with RA and PsA. MATERIALS AND METHODS: One hundred and forty-one patients with RA, 65 patients with PsA and 45 healthy controls (HC) were included in the current study. US assessment of the wrist, second and third metacarpophalangeal, second and third proximal interphalangeal joint, second and fifth metatarsophalangeal joint was performed, and the following scores were calculated: synovitis and tenosynovitis/paratenonitis scores on gray scale ultrasound (GSUS) and on power Doppler (PD) US, erosion score, US7 score. RESULTS: RA patients had significantly higher median scores of GS synovitis, PD synovitis, erosions and US7 than PsA patients (p < 0.001). PsA patients had significantly higher median scores of GS tenosynovitis/paratenonitis and PD tenosynovitis/paratenonitis (p < 0.001). All US scores were significantly higher for both patient groups as compared to the HC group (p < 0.001). CONCLUSION: Sonographic evaluation by a seven-joint score can be helpful in the differentiation between rheumatoid and psoriatic arthritis. | |
| 34033406 | Tocilizumab. | 2022 Jan | Tocilizumab is FDA-indicated for the adult treatment of rheumatoid arthritis and giant cell arteritis and pediatric treatment of polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. Tocilizumab has a non-FDA-indicated use in the treatment of COVID-19 pneumonia. This activity highlights the role of the interprofessional team in managing patients prescribed tocilizumab for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. | |
| 35252279 | Highlights of Strategies Targeting Fibroblasts for Novel Therapies for Rheumatoid Arthriti | 2022 | Synovial fibroblasts of rheumatoid arthritis (RA) play a critical role in perpetuation of chronic inflammation by interaction with immune and inflammatory cells and in cartilage and bone invasion, but current therapies for RA are not directly targeted fibroblasts. Selectively fibroblast targeted therapy has been hampered because of lack of fibroblast specific molecular signature. Recent advancement in technology enabled us to gain insightful information concerning RA synovial fibroblast subpopulations and functions. Exploring fibroblast targeted therapies have been focused on inducing cell death via fibroblast associated proteins; interrupting fibroblast binding to matrix protein; blocking intercellular signaling between fibroblasts and endothelial cells; inhibiting fibroblast proliferation and invasion; promoting cell apoptosis and inducing cellular senescence, and modulating fibroblast glucose metabolism. Translation into clinical studies of these fibroblast targeted strategies is required for evaluation for their clinical application, in particular for combination therapy with current immune component targeted therapies. Here, several strategies of fibroblast targeted therapy are highlighted. |